Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors
Caroline Flament, Niels Halama, Dirk Jäger, Alexander Eggermont, Sylvie Bonvalot, Frédéric Commo, Philippe Terrier, Paule Opolon, Jean‐François Emile, Jean‐Michel Coindre, Guido Guido Kroemer, Nathalie Chaput, Axel Le Cesne, Jean‐Yves Blay, Laurence Zitvogel, Sylvie Rusakiewicz, Michaëla Semeraro, Matthieu Sarabi, Mélanie Desbois, Clara Locher, R. Méndez, Nadège Vimond, Ángel Concha, Federico Garrido, Nicolás Isambert, L. Chaigneau, Valérie Le Brun-Ly, Patrice Dubreuil, Isabelle Cremer, Anne Caignard, Vichnou Poirier-Colame, Kariman Chaba (2013). Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors. , 73(12), DOI: https://doi.org/10.1158/0008-5472.can-13-0371.
Article285 days agoExpression of antibody–drug conjugate targets in soft tissue sarcomas
François Bertucci, Pascal Finetti, Lénaïg Mescam, Audrey Monneur, A Frejafon, Axel Le Cesne, Isabelle Treilleux, Antoîne Italiano, M. Brahmi, Jean Yves Blay, Émilie Mamessier (2025). Expression of antibody–drug conjugate targets in soft tissue sarcomas. , 10(10), DOI: https://doi.org/10.1016/j.esmoop.2025.105837.
Article19 days agoEE275 Economic Evaluation of Adjuvant Chemotherapy for Soft Tissue Sarcoma Using Linked NETSARC+ (French Registry) and SNDS (French National Health Data System) Real World Data: The Deepsarc Study
Lionel Perrier, Magali Morelle, Sylvie Bonvalot, Claire Chemin, Hugo Crochet, Anne Ducassou, Françoise Ducimetière, F. Gouin, André Happe, Noémie Huchet, François Le Loarer, Axel Le Cesne, C. Llacer, Simone Mathoulin-Pelissier, Pierre Méeus, Daniel Orbach, V. Thevenet, Maud Toulmonde, Gualter Vaz, Nicolas Penel, Jean Yves Blay (2025). EE275 Economic Evaluation of Adjuvant Chemotherapy for Soft Tissue Sarcoma Using Linked NETSARC+ (French Registry) and SNDS (French National Health Data System) Real World Data: The Deepsarc Study. , 28(6), DOI: https://doi.org/10.1016/j.jval.2025.04.1874.
Article19 days agoUpdated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE
Michael C. Heinrich, Jean Yves Blay, Hans Gelderblom, Suzanne George, Patrick Schöffski, Margaret von Mehren, John Zalcberg, Robin L. Jones, Yoon‐Koo Kang, Albiruni R. Abdul Razak, Jonathan C. Trent, Steven Attia, Axel Le Cesne, Kjetil Boye, David Goldstein, César Sánchez, Brittany L. Siontis, P. H. Cox, Erika Davis, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Sebastian Bauer (2025). Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE. , 43(20), DOI: https://doi.org/10.1200/jco-24-02818.
Article19 days agoLong-term clinical outcome assessments in patients with tenosynovial giant cell tumor treated with vimseltinib: 1-year results from the MOTION phase 3 trial.
Vivek A. Bhadri, Hans Gelderblom, Silvia Stacchiotti, Sebastian Bauer, Andrew J. Wagner, Michiel A. J. van de Sande, Nicholas M. Bernthal, Antonio López–Pousa, Albiruni Ryan Abdul Razak, Antoîne Italiano, Mahbubl Ahmed, Axel Le Cesne, Christopher Tait, Amanda Saunders, Nicholas Zeringo, B. Harrow, Maitreyi G. Sharma, Matthew L. Sherman, Jean Yves Blay, William D. Tap (2025). Long-term clinical outcome assessments in patients with tenosynovial giant cell tumor treated with vimseltinib: 1-year results from the MOTION phase 3 trial.. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.11558.
Article19 days ago